Entrada Therapeutics, Inc.
TRDA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $645,021 | $498,729 | $423,086 | $534,561 |
| - Cash | $101,211 | $67,602 | $45,157 | $291,064 |
| + Debt | $59,207 | $68,230 | $25,936 | $0 |
| Enterprise Value | $603,017 | $499,357 | $403,865 | $243,497 |
| Revenue | $210,782 | $129,013 | $0 | $0 |
| % Growth | 63.4% | – | – | – |
| Gross Profit | $210,782 | $129,013 | $0 | $0 |
| % Margin | 100% | 100% | – | – |
| EBITDA | $50,784 | -$321 | -$95,353 | -$50,010 |
| % Margin | 24.1% | -0.2% | – | – |
| Net Income | $65,626 | -$6,685 | -$94,616 | -$51,158 |
| % Margin | 31.1% | -5.2% | – | – |
| EPS Diluted | 1.68 | -0.2 | -2.79 | -1.6 |
| % Growth | 940% | 92.8% | -74.4% | – |
| Operating Cash Flow | -$41,557 | $139,803 | -$93,786 | -$50,862 |
| Capital Expenditures | -$3,158 | -$5,614 | -$2,887 | -$4,580 |
| Free Cash Flow | -$44,715 | $134,189 | -$96,673 | -$55,442 |